New combo therapy may cut need for frequent eye shots in macular degeneration

NCT ID NCT00527475

Completed Disease control Sponsor: Texas Retina Associates Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a light-based treatment (photodynamic therapy) to the standard drug ranibizumab could reduce the number of eye injections needed for wet macular degeneration. Sixty adults over age 50 with the condition took part. The goal was to see if the combination worked as well as ranibizumab alone while requiring fewer injections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration Neovascularization, Pathologic wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MACULAR DEGENERATION

Contacts and locations

Show contact details

Locations

Associated Retinal Consultants

Ann Arbor, Michigan, 49301, United States
California Retina Consultants & Research Foundation

Santa Barbara, California, 93103, United States
Texas Retina Associates

Arlington, Texas, 76012, United States